$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

암환자의 우울증과 카켁시아 간 시토카인 매개 연결
The Cytokine-mediated Link Between Depression and Cachexia in Cancer Patients 원문보기

대한물리치료과학회지 = Journal of Korean Physical Therapy Science, v.26 no.3, 2019년, pp.44 - 56  

임우택 (우송대학교 물리치료학과)

Abstract AI-Helper 아이콘AI-Helper

Despite the advances in medical technology, there are limited therapeutic interventions for cancer. Currently, the main goal of treatment is to remove a tumor completely. However, recent studies have shown that mortality is highly influenced by symptoms such as depression and cachexia, not solely by...

주제어

AI 본문요약
AI-Helper 아이콘 AI-Helper

* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.

문제 정의

  • 본 종설에서는 시토카인이 인체에 미치는 역할을 바탕으로, 두 중요한 임상적 증후의 연관성을 고찰하고자 한다. 이는 암 환자의 생존기간(survival time), 생존율(survival rate)과 매우 밀접한 관계에 있으며, 건강 증진 외 삶의 질 개선에서도 매우 중요한 부분으로 고려될 수 있다.
본문요약 정보가 도움이 되었나요?

질의응답

핵심어 질문 논문에서 추출한 답변
현재의 암 치료의 특징은 무엇인가 현재 암 치료는 대부분 암세포를 직접 사멸하거나 줄이기 위한 치료가 대부분이며, 암 발생 이후 부가적 으로 나타나는 임상적 증상을 위한 치료에는 상대적 으로 큰 노력이 이루어지고 있지 않다. 하지만 최근 연구에 따르면, 암 환자 중 상당수는 암이 아닌 부가적 증상으로 먼저 사망에 이른다는 것이 밝혀지고 있다.
암 환자의 증가가 가족과 사회의 문제로 확대되는 이유는 무엇인가 암 환자의 증가는 환자 개인의 문제를 넘어 가족과 사회의 문제로 확대된다. 암은 생명을 위협 (life-threatening)하는 질환으로 환자는 암 진단과 함께 극심한 스트레스를 겪는 것이 일반적이며(Zabora 등, 2001), 이것은 우울증과 같은 정신적 문제 역시 일으 키며, 독립적 활동 및 사회적 참여의 저하를 가져온다.
시토카인이란 무엇인가 사실 시토카인은 큰 포식세포(macrophage)와 림프구 (lymphocyte)에 의해 방출되는 가용성 매개물질 (soluble mediator)로 면역 체계에서 긍정적 측면과 부정적 측면을 동시에 갖는다. 시토카인의 생성은 T도움세포(T helper cell)의 기능적 활동에 따라 크게 두 가지로 분류된다.
질의응답 정보가 도움이 되었나요?

참고문헌 (85)

  1. Aass N, Fossa SD, Dahl AA, et al. Prevalence of anxiety and depression in cancer patients seen at the Norwegian Radium Hospital. Eur J Cancer. 1997;33(10):1597-1604. 

  2. Arai H, Ouchi Y, Toba K, et al. Japan as the front-runner of super-aged societies: Perspectives from medicine and medical care in Japan. Geriatr Gerontol Int. 2015;15(6):673-687. 

  3. Argiles JM, Busquets S, Lopez-Soriano FJ. Anti-inflammatory therapies in cancer cachexia. Eur J Pharmacol. 2011;668 Suppl 1:S81-86. 

  4. Argiles JM, Lopez-Soriano FJ. The role of cytokines in cancer cachexia. Med Res Rev. 1999;19(3):223-248. 

  5. Baltgalvis KA, Berger FG, Pena MMO, et al. Interleukin-6 and cachexia in ApcMin/+ mice. Am J Physiol Regul Integr Comp Physiol. 2008;294(2):R393-401. 

  6. Berard RM, Boermeester F, Viljoen G. Depressive disorders in an out-patient oncology setting: prevalence, assessment, and management. Psychooncology. 1998;7(2):112-120. 

  7. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 2007;81(1):1-5. 

  8. Black PH. Central nervous system-immune system interactions: psychoneuroendocrinology of stress and its immune consequences. Antimicrob Agents Chemother. 1994;38(1):1-6. 

  9. Bodurka-Bevers D, Basen-Engquist K, Carmack CL, et al. Depression, anxiety, and quality of life in patients with epithelial ovarian cancer. Gynecol Oncol. 2000;78(3 Pt 1):302-308. 

  10. Bossola M, Muscaritoli M, Costelli P, et al. Increased muscle ubiquitin mRNA levels in gastric cancer patients. Am J Physiol Regul Integr Comp Physiol. 2001;280(5):R1518-1523. 

  11. Bruera E, Neumann CM, Pituskin E, et al. Thalidomide in patients with cachexia due to terminal cancer: preliminary report. Ann Oncol. 1999;10(7):857-859. 

  12. Buccheri G. Depressive reactions to lung cancer are common and often followed by a poor outcome. Eur Respir J. 1998;11(1):173-178. 

  13. Busquets S, Aranda X, Ribas-Carbo M, et al. Tumour necrosis factor-alpha uncouples respiration in isolated rat mitochondria. Cytokine. 2003;22(1-2):1-4. 

  14. Caan BJ, Meyerhardt JA, Kroenke CH, et al. Explaining the Obesity Paradox: The Association between Body Composition and Colorectal Cancer Survival (C-SCANS Study). Cancer Epidemiol Biomarkers Prev. 2017;26(7):1008-1015. 

  15. Caan BJ, Cespedes Feliciano EM, Prado CM, et al. Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Nonmetastatic Breast Cancer. JAMA Oncol. 2018;4(6):798-804. 

  16. Carroll BT, Kathol RG, Noyes R, et al. Screening for depression and anxiety in cancer patients using the Hospital Anxiety and Depression Scale. Gen Hosp Psychiatry. 1993;15(2):69-74. 

  17. Chen ML, Chang HK, Yeh CH. Anxiety and depression in Taiwanese cancer patients with and without pain. J Adv Nurs. 2000;32(4):944-951. 

  18. Chochinov HM, Wilson KG, Enns M, et al. 'Are you depressed?' Screening for depression in the terminally ill. Am J Psychiatry. 1997;154(5):674-676. 

  19. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med. 1995;332(20):1351-1362. 

  20. Ciaramella A, Poli P. Assessment of depression among cancer patients: the role of pain, cancer type and treatment. Psychooncology. 2001;10(2):156-165. 

  21. Cohen S, Nathan JA, Goldberg AL. Muscle wasting in disease: molecular mechanisms and promising therapies. Nat Rev Drug Discov. 2015;14(1):58-74. 

  22. Colon EA, Callies AL, Popkin MK, et al. Depressed mood and other variables related to bone marrow transplantation survival in acute leukemia. Psychosomatics. 1991;32(4):420-425. 

  23. Costelli P, Carbo N, Tessitore L, et al. Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model. J Clin Invest. 1993;92(6):2783-2789. 

  24. Cwikel JG, Behar LC, Zabora J. Psychosocial factors that affect the survival of adult cancer patients: A review of research. Journal of psychosocial oncology. 1997;15(3-4):1-34. 

  25. Dalton SO, Schuz J, Engholm G, et al. Social inequality in incidence of and survival from cancer in a population-based study in Denmark, 1994-2003: Summary of findings. Eur J Cancer. 2008;44(14):2074-2085. 

  26. De Leeuw JR, De Graeff A, Ros WJ, et al. Negative and positive influences of social support on depression in patients with head and neck cancer: a prospective study. Psychooncology. 2000;9(1):20-28. 

  27. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160(14):2101-2107. 

  28. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59(12):1116-1127. 

  29. Fearon KCH, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012;16(2):153-166. 

  30. Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol. 2013;10(2):90-99. 

  31. Flynn MG, McFarlin BK. Toll-like receptor 4: link to the anti-inflammatory effects of exercise? Exerc Sport Sci Rev. 2006;34(4):176-181. 

  32. Fong Y, Moldawer LL, Marano M, et al. Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins. Am J Physiol. 1989;256(3 Pt 2):R659-665. 

  33. Glaser R, Kiecolt-Glaser JK. Stress-induced immune dysfunction: implications for health. Nat Rev Immunol. 2005;5(3):243-251. 

  34. Goldberg JA, Scott RN, Davidson PM, et al. Psychological morbidity in the first year after breast surgery. Eur J Surg Oncol. 1992;18(4):327-331. 

  35. Grassi L, Rosti G, Albieri G, et al. Depression and abnormal illness behavior in cancer patients. Gen Hosp Psychiatry. 1989;11(6):404-411. 

  36. Holsboer F, Ising M. Central CRH system in depression and anxiety--evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol. 2008;583(2-3):350-357. 

  37. Hopwood P, Stephens RJ. Depression in patients with lung cancer: prevalence and risk factors derived from quality-of-life data. J Clin Oncol. 2000;18(4):893-903. 

  38. Irwin MR, Miller AH. Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun. 2007;21(4):374-383. 

  39. Kathol RG, Mutgi A, Williams J, et al. Diagnosis of major depression in cancer patients according to four sets of criteria. Am J Psychiatry. 1990;147(8):1021-1024. 

  40. Kelsen DP, Portenoy RK, Thaler HT, et al. Pain and depression in patients with newly diagnosed pancreas cancer. J Clin Oncol. 1995;13(3):748-755. 

  41. Kenis G, Maes M. Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol. 2002;5(4):401-412. 

  42. Kiecolt-Glaser JK, Glaser R. Depression and immune function: central pathways to morbidity and mortality. J Psychosom Res. 2002;53(4):873-876. 

  43. Kim YK, Maes M. The role of the cytokine network in psychological stress. Acta Neuropsychiatr. 2003;15(3):148-155. 

  44. Kissane DW, Clarke DM, Ikin J, et al. Psychological morbidity and quality of life in Australian women with early-stage breast cancer: a cross-sectional survey. Med J Aust. 1998;169(4):192-196. 

  45. Klausner JD, Makonkawkeyoon S, Akarasewi P, et al. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;11(3):247-257. 

  46. Kuchler T, Henne-Bruns D, Rappat S, et al. Impact of psychotherapeutic support on gastrointestinal cancer patients undergoing surgery: survival results of a trial. Hepatogastroenterology. 1999;46(25):322-335. 

  47. Kugaya A, Akechi T, Okuyama T, et al. Prevalence, predictive factors, and screening for psychologic distress in patients with newly diagnosed head and neck cancer. Cancer. 2000;88(12):2817-2823. 

  48. Kuroda K, Nakashima J, Kanao K, et al. Interleukin 6 is associated with cachexia in patients with prostate cancer. Urology. 2007;69(1):113-117. 

  49. Lansky SB, List MA, Herrmann CA, et al. Absence of major depressive disorder in female cancer patients. J Clin Oncol. 1985;3(11):1553-1560. 

  50. Lasry JC, Margolese RG, Poisson R, et al. Depression and body image following mastectomy and lumpectomy. J Chronic Dis. 1987;40(6):529-534. 

  51. Laviano A, Meguid MM, Inui A, et al. Therapy insight: Cancer anorexia-cachexia syndrome--when all you can eat is yourself. Nat Clin Pract Oncol. 2005;2(3):158-165. 

  52. Linden W, Vodermaier A, Mackenzie R, et al. Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age. J Affect Disord. 2012;141(2-3):343-351. 

  53. Little JP, Phillips SM. Resistance exercise and nutrition to counteract muscle wasting. Appl Physiol Nutr Metab. 2009;34(5):817-828. 

  54. Lundholm K, Gelin J, Hyltander A, et al. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res. 1994;54(21):5602-5606. 

  55. Mantovani G, Maccio A, Mura L, et al. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med. 2000;78(10):554-561. 

  56. Massie, M. J., and M. K. Popkin. "Depressive disorders. en Psycho-oncology. Editor: Jimmie C. Holland.";1998.p.518-540. 

  57. McCorkle R, Strumpf NE, Nuamah IF, et al. A specialized home care intervention improves survival among older post-surgical cancer patients. J Am Geriatr Soc. 2000;48(12):1707-1713. 

  58. McMillan DC, Leen E, Smith J, et al. Effect of extended ibuprofen administration on the acute phase protein response in colorectal cancer patients. Eur J Surg Oncol. 1995;21(5):531-534. 

  59. Mishel MH, Hostetter T, King B, et al. Predictors of psychosocial adjustment in patients newly diagnosed with gynecological cancer. Cancer Nurs. 1984;7(4):291-299. 

  60. Monk JP, Phillips G, Waite R, et al. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol. 2006;24(12):1852-1859. 

  61. Musselman DL, Miller AH, Porter MR, et al. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry. 2001;158(8):1252-1257. 

  62. Newport DJ, Nemeroff CB. Assessment and treatment of depression in the cancer patient. J Psychosom Res. 1998;45(3):215-237. 

  63. Pace TWW, Hu F, Miller AH. Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav Immun. 2007;21(1):9-19. 

  64. Pascoe S, Edelman S, Kidman A. Prevalence of psychological distress and use of support services by cancer patients at Sydney hospitals. Aust N Z J Psychiatry. 2000;34(5):785-791. 

  65. Pinder KL, Ramirez AJ, Black ME, et al. Psychiatric disorder in patients with advanced breast cancer: prevalence and associated factors. Eur J Cancer. 1993;29A(4):524-527. 

  66. Pinquart M, Duberstein PR. Depression and cancer mortality: a meta-analysis. Psychol Med. 2010; 40(11):1797-1810. 

  67. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27(1):24-31. 

  68. Raison CL, Miller AH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry. 2003;160(9):1554-1565. 

  69. Reid J, Mills M, Cantwell M, et al. Thalidomide for managing cancer cachexia. Cochrane Database Syst Rev. 2012;(4):CD008664. 

  70. Richardson JL, Shelton DR, Krailo M, et al. The effect of compliance with treatment on survival among patients with hematologic malignancies. J Clin Oncol. 1990;8(2):356-364. 

  71. Schlesinger S, Siegert S, Koch M, et al. Postdiagnosis body mass index and risk of mortality in colorectal cancer survivors: a prospective study and meta-analysis. Cancer Causes Control. 2014;25(10):1407-1418. 

  72. Shachar SS, Deal AM, Weinberg M, et al. Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane Based Chemotherapy. Clin Cancer Res. 2017;23(3):658-665. 

  73. Skarstein J, Aass N, Fossa SD, et al. Anxiety and depression in cancer patients: relation between the Hospital Anxiety and Depression Scale and the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire. J Psychosom Res. 2000;49(1):27-34. 

  74. Soygur H, Palaoglu O, Akarsu ES, et al. Interleukin-6 levels and HPA axis activation in breast cancer patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(6):1242-1247. 

  75. Spiegel D, Bloom JR, Yalom I. Group support for patients with metastatic cancer. A randomized outcome study. Arch Gen Psychiatry. 1981;38(5):527-533. 

  76. Spiegel D, Giese-Davis J. Depression and cancer: mechanisms and disease progression. Biol Psychiatry. 2003;54(3):269-282. 

  77. Stefanek ME, Derogatis LP, Shaw A. Psychological distress among oncology outpatients. Prevalence and severity as measured with the Brief Symptom Inventory. Psychosomatics. 1987;28(10):530-532, 537-539. 

  78. Thomas DR. Distinguishing starvation from cachexia. Clin Geriatr Med. 2002;18(4):883-891. 

  79. Tisdale MJ. Biology of cachexia. J Natl Cancer Inst. 1997;89(23):1763-1773. 

  80. Torelli GF, Meguid MM, Moldawer LL, et al. Use of recombinant human soluble TNF receptor in anorectic tumor-bearing rats. Am J Physiol. 1999;277(3):R850-855. 

  81. Wang H, Hai S, Liu Y, et al. Skeletal Muscle Mass as a Mortality Predictor among Nonagenarians and Centenarians: A Prospective Cohort Study. Sci Rep. 2019;9(1):2420. 

  82. Wulsin LR, Vaillant GE, Wells VE. A systematic review of the mortality of depression. Psychosom Med. 1999;61(1):6-17. 

  83. Zabora J, BrintzenhofeSzoc K, Curbow B, et al. The prevalence of psychological distress by cancer site. Psychooncology. 2001;10(1):19-28. 

  84. Zaki MH, Nemeth JA, Trikha M. CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Int J Cancer. 2004;111(4):592-595. 

  85. Zhu CB, Carneiro AM, Dostmann WR, et al. p38 MAPK activation elevates serotonin transport activity via a trafficking-independent, protein phosphatase 2A-dependent process. J Biol Chem. 2005; 280(16):15649-15658. 

관련 콘텐츠

이 논문과 함께 이용한 콘텐츠

저작권 관리 안내
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로